Lunit
Founded Year
2013Stage
IPO | IPOTotal Raised
$135.87MDate of IPO
7/21/2022About Lunit
Lunit operates as a medical artificial intelligence (AI) software company. Lunit AI solutions help discover cancer and predict cancer treatment response by finding the right diagnosis at the right costs and the right treatment for the right patients. It was founded in 2013 and is based in Seoul, South Korea.
Loading...
Lunit's Product Videos
Lunit's Products & Differentiators
Lunit INSIGHT Suite
The Lunit INSIGHT Suite, Lunit’s AI solution for radiology, mainly consists of 3 AI solutions for cancer screening and diagnosis: Lunit INSIGHT CXR (chest x-ray image analysis), Lunit INSIGHT MMG (mammogram analysis), and Lunit INSIGHT DBT (digital breast tomosynthesis image analysis; soon to be launched). The most mature products within the series—Lunit INSIGHT CXR and Lunit INSIGHT MMG—provide AI-powered detection of lesions that are suspicious of chest abnormalities and breast cancer with 96-99% accuracy. Lunit INSIGHT DBT, the latest product to be released in our radiology suite, is designed to accelerate reading by identifying the 3D slice image showing the suspected breast cancer lesion among multiple layers of images.
Loading...
Research containing Lunit
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Lunit in 3 CB Insights research briefs, most recently on Dec 7, 2022.
Expert Collections containing Lunit
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Lunit is included in 4 Expert Collections, including Artificial Intelligence.
Artificial Intelligence
10,988 items
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health 50
450 items
The most promising digital health startups transforming the healthcare industry
Digital Health
10,714 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Oncology Tech
457 items
This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.
Lunit Patents
Lunit has filed 64 patents.
The 3 most popular patent topics include:
- machine learning
- artificial neural networks
- artificial intelligence
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/13/2020 | 11/28/2023 | Machine learning, Artificial neural networks, Learning methods, 3D imaging, Classification algorithms | Grant |
Application Date | 11/13/2020 |
|---|---|
Grant Date | 11/28/2023 |
Title | |
Related Topics | Machine learning, Artificial neural networks, Learning methods, 3D imaging, Classification algorithms |
Status | Grant |
Latest Lunit News
Dec 1, 2023
Lunit selected as contractor for building medical AI platform in Singapore The S.Korean AI medical company will supply Lunit Insight CXR to local public hospitals By Lunit'sгҖҖInsightгҖҖCXR South Korean medical AI company Lunit announced on Friday that it has been selected as the final contractor in the bidding for the establishment of the medical AI platform "AimSG" by SYNAPSE, Singapore's state-owned healthtech agency, aimed at innovating public healthcare services. As a result, Lunit will provide its chest X-ray AI image analysis solution, "Lunit Insight CXR," to local public hospitals. According to Lunit, SYNAPSE is a government agency responsible for the integrated management of IT systems in Singapore's public hospitals. To manage medical data in Singapore's public hospitals, it is mandatory to utilize the systems of this agency. SYNAPSE plans to install the AimSG service in major public hospitals in Singapore. Once installed, Lunit's AI solution will be utilized in all hospitals, according to Lunit. Lunit expects positive effects on medical innovation through the use of AI, anticipating improved diagnostic accuracy and shortened treatment times for local medical professionals. "This collaboration with SYNAPSE will be an opportunity to boast our company's global competitiveness, significantly contributing to public healthcare innovation in Singapore," said Suh Beom-Seok, CEO of Lunit. "Particularly, since Singapore plays a central role in the ASEAN region, our success here is expected to serve as a foundation for expanding throughout the entire ASEAN region," he added. Write to Hyun-Ah Oh at 5hyun@hankyung.com 1 Min read 1 Min read 2 Min read 1 Min read 1 Min read
Lunit Frequently Asked Questions (FAQ)
When was Lunit founded?
Lunit was founded in 2013.
Where is Lunit's headquarters?
Lunit's headquarters is located at 15F, 27, Teheran-ro 2-gil, Seoul.
What is Lunit's latest funding round?
Lunit's latest funding round is IPO.
How much did Lunit raise?
Lunit raised a total of $135.87M.
Who are the investors of Lunit?
Investors of Lunit include HealthQuest Capital, Tybourne Capital Management, BrightEdge, NSG Ventures, Casdin Capital and 18 more.
Who are Lunit's competitors?
Competitors of Lunit include DeepBio, Coreline Soft, Ibex, Qure.ai, Kheiron Medical Technologies and 7 more.
What products does Lunit offer?
Lunit's products include Lunit INSIGHT Suite and 1 more.
Who are Lunit's customers?
Customers of Lunit include Leeds University Hospital.
Loading...
Compare Lunit to Competitors
Qure.ai provides an artificial intelligence (AI) based system to identify abnormalities in head computed tomography (CT) scans. It leverages deep learning to diagnose diseases from radiology and pathology imaging and create personalized cancer treatment plans from psychopathology imaging and genome sequences. The company was founded in 2016 and is based in Mumbai, India.
Aidoc provides a care coordination platform. It offers a wide range of solutions such as real-time notifications for neuro care, automatic analysis of imaging to identify abnormalities, and more. It was founded in 2016 and is based in Tel Aviv, Israel.
Kheiron Medical Technologies operates as a healthcare software company. It helps cancer patients by analyzing medical images and helps to enable the automation of radiology reporting tasks. It was formerly known as Maesterai. The company was founded in 2016 and is based in London, United Kingdom.
Arterys is a company that focuses on the integration of artificial intelligence and data in the medical sector, specifically in the domain of radiology. The company offers a cloud-based platform that uses AI to extract actionable insights from medical images, aiming to improve diagnostic decision making, efficiency, and productivity. Its services primarily cater to the healthcare industry. Arterys was formerly known as Morpheus Medical, Inc.. It was founded in 2011 and is based in San Francisco, California.
Quibim, a company with its headquarters in Valencia, Spain, provides a whole-body medical imaging analysis. Quibim products are used worldwide by a huge diversity of research and care teams. Partners use Quibim Precision, a CE-marked whole-body imaging ecosystem, for a wide range of applications from detecting a disease to tracking the efficacy of treatments. Quibim follows an AI-first approach to help detect pathologies across every body part and imaging modality, using quantitative imaging biomarkers.
MaxQ AI is a company focused on artificial intelligence and clinical workflow automation in the healthcare sector. The company offers innovative software solutions that interpret medical images and patient data, assisting physicians in making faster and more accurate decisions in diagnosing serious conditions such as intracranial hemorrhage, stroke, and brain trauma. The primary customers of MaxQ AI are physicians and healthcare providers. MaxQ AI was formerly known as MedyMatch. It was founded in 2013 and is based in Tel Aviv, Israel.
Loading...